BioLineRx Ltd. (BLRX) announced Monday morning that it has signed a worldwide, exclusive license agreement with Genoscience and RFS Pharma to develop and commercialize BL-8030, an oral treatment for Hepatitis C.
BioLineRx gapped open sharply higher Monday and has continued to rise on above average volume. Shares are now up 1.58 at $5.70 and have set a week and a half high.
For comments and feedback: editorial@rttnews.com